Multicenter EXCYTE-2 Study to Evaluate the Precision Medicine Platform in Patients With Acute Myeloid Leukemia
Exscientia plc announced the launch of EXCYTE-2, an observational clinical trial in acute myeloid leukemia (AML), known as. This study aims to examine the relationship between ex vivo drug response (EVDR), measured on individual cells in...
VantAI, a leader in generative AI and drug discovery, announced the appointment of Jae Won Kim as Chief Operating Officer (COO) and Chief Financial Officer (CFO). Ms. Kim is an experienced finance, corporate development, and operations executive with a strong track record, especially in drug discovery and the induced...
Helio Genomics, an AI-driven healthcare company specializing in diagnostics technology and test development for cancer detection, has announced that Gary Frazier has been selected as Chief Growth Officer for the firm. Frazier brings extensive experience in several key aspects of healthcare to the position.
Frazier is the founder and CEO of two...
In recent years, the integration of artificial intelligence (AI) has sparked a transformative shift in the way we approach healthcare, disease diagnosis, and drug discovery. With the ability to process vast amounts of data and identify complex patterns, AI has become an indispensable tool in the pursuit of innovative...
Novel solution distinguishes 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC) revealing unprecedented insights into current and future states of disease using one 5ng DNA sample
biomodal, an omics-based life sciences technology and analytics company, announced it is delivering the 6-base genome to customers with the launch of duet multiomics solution evoC (duet...
Takara Bio USA, Inc., a wholly owned subsidiary of Takara Bio Inc., announced plans to launch two critical solutions for oncology research. These automated single-cell total RNA-seq and DNA-seq library preparation kits will provide high sample and cell throughput, less hands-on time, and the ability to capture more information...
Matica Biotechnology, Inc., a contract development and manufacturing organization (CDMO) of cell and gene therapies (CGTs), announced the appointment of Paul Kim as chief executive officer (CEO).
As incoming CEO, Kim will manage daily operations and provide strategic direction to Matica Bio as it rapidly expands its capacity and capabilities...
resTOR to be the first longevity clinic nationwide to offer the Company's blood-based epigenetic-genetic cardiovascular disease tests
Cardio Diagnostics Holdings, Inc., an AI-driven precision cardiovascular medicine company, announces that Houston-based resTOR Longevity Clinic will integrate Cardio Diagnostics' solutions into its battery of tests for new patients in its longevity-focused concierge...
The Echo® MS+ system unlocks enhanced high-throughput screening capability by bringing acoustic ejection mass spectrometry (AEMS) approaches to the SCIEX ZenoTOF 7600 system.
SCIEX, a global leader in life science analytical technologies, launches the Echo® MS+ system at SLAS 2024. The system couples proprietary Acoustic Ejection Mass Spectrometry technology and...
Napp Pharmaceuticals Limited, a member of the international network of Mundipharma independent associated companies, announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) has authorised rezafungin for the treatment of invasive candidiasis in adults in Great Britain (GB).
The authorisation was based on positive results from the pivotal ReSTORE...
